Xenon Pharmaceuticals Inc. (XENE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '13: 27.4M Q1 '14: 27M Q2 '14: 26.7M Q3 '14: 29.1M Q4 '14: 28.4M Q1 '15: 27.4M Q2 '15: 26.1M Q3 '15: 17.2M Q4 '15: 15.6M Q1 '16: 12.2M Q2 '16: 8.5M Q3 '16: 4.7M Q4 '16: 1.8M Q1 '17: 1.2M Q2 '17: 820K Q3 '17: 671K Q4 '17: 311K Q2 '20: 27.3M Q3 '20: 30.3M Q4 '20: 32.2M Q1 '21: 29.4M Q2 '21: 18.3M Q3 '21: 19.9M Q4 '21: 18.4M Q1 '22: 22.8M Q2 '22: 21.2M Q3 '22: 13.2M Q4 '22: 9.4M Q4 '24: 0 Q1 '25: 7.5M Q2 '25: 7.5M Q3 '25: 7.5M Q4 '25: 7.5M Q1 '26: 0 Q2 '26: 0 Q4 '14 Q1 '16 Q2 '17 Q4 '20 Q1 '22 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '13: 9.7M Q1 '14: 8.8M Q2 '14: 10.9M Q3 '14: 13.1M Q4 '14: 11.1M Q1 '15: 3.9M Q2 '15: 2.8M Q3 '15: -6.7M Q4 '15: -9.4M Q1 '16: -8.9M Q2 '16: -15.4M Q3 '16: -22M Q4 '16: -24.8M Q1 '17: -27.1M Q2 '17: -28.7M Q3 '17: -30M Q4 '17: -32.6M Q1 '18: -32.4M Q2 '18: -32.1M Q3 '18: -37.6M Q4 '18: -38M Q1 '19: -42M Q2 '19: -44.9M Q3 '19: -39.7M Q4 '19: -42.8M Q1 '20: -39.1M Q2 '20: -29.2M Q3 '20: -30M Q4 '20: -31.3M Q1 '21: -39.3M Q2 '21: -61.2M Q3 '21: -67.1M Q4 '21: -79M Q1 '22: -80.3M Q2 '22: -88.1M Q3 '22: -110.7M Q4 '22: -129.1M Q1 '23: -160.8M Q2 '23: -186.1M Q3 '23: -203.7M Q4 '23: -214.1M Q1 '24: -224M Q2 '24: -237.5M Q3 '24: -255.5M Q4 '24: -279.3M Q1 '25: -293M Q2 '25: -318.1M Q3 '25: -340.8M Q4 '25: -373.1M Q1 '26: -412.7M Q2 '26: -441.6M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '14: 11.5M Q3 '14: 14.3M Q4 '14: 13M Q1 '15: 2.5M Q2 '15: 2.4M Q3 '15: -10.6M Q4 '15: -15.8M Q1 '16: -9.9M Q2 '16: -17M Q3 '16: -20.9M Q4 '16: -23M Q1 '17: -27.3M Q2 '17: -28.6M Q3 '17: -28.6M Q4 '17: -30.7M Q1 '18: -26.9M Q2 '18: -27.4M Q3 '18: -34M Q4 '18: -34.5M Q1 '19: -42.1M Q2 '19: -44.3M Q3 '19: -38.8M Q4 '19: -41.6M Q1 '20: -37.7M Q2 '20: -27.9M Q3 '20: -27.9M Q4 '20: -28.8M Q1 '21: -37.1M Q2 '21: -59.1M Q3 '21: -65.6M Q4 '21: -78.9M Q1 '22: -82.8M Q2 '22: -91.8M Q3 '22: -113.5M Q4 '22: -125.4M Q1 '23: -147.4M Q2 '23: -163.7M Q3 '23: -175M Q4 '23: -182.4M Q1 '24: -188.6M Q2 '24: -199.1M Q3 '24: -213.4M Q4 '24: -234.3M Q1 '25: -251.4M Q2 '25: -278.2M Q3 '25: -306.3M Q4 '25: -345.9M Q1 '26: -383.2M Q2 '26: -409.2M Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '14: 531K Q4 '14: 266K Q1 '15: -4.4M Q2 '15: -4.6M Q3 '15: -15.8M Q4 '15: -18.1M Q1 '16: -17.5M Q2 '16: -20.5M Q3 '16: -20.1M Q4 '16: -19.6M Q1 '17: -21.1M Q2 '17: -22.5M Q3 '17: -26.6M Q4 '17: -28.7M Q1 '18: -30.5M Q2 '18: -29.2M Q3 '18: -34.3M Q4 '18: -34.7M Q1 '19: -35.2M Q2 '19: -38.4M Q3 '19: -31.7M Q4 '19: -4.7M Q1 '20: -9.1M Q2 '20: -11.1M Q3 '20: -15.2M Q4 '20: -48.1M Q1 '21: -55.8M Q2 '21: -58.1M Q3 '21: -61.9M Q4 '21: -69.5M Q1 '22: -67.2M Q2 '22: -71M Q3 '22: -86.4M Q4 '22: -101M Q1 '23: -117M Q2 '23: -133.4M Q3 '23: -151M Q4 '23: -151.1M Q1 '24: -162.9M Q2 '24: -160.8M Q3 '24: -162.4M Q4 '24: -181.4M Q1 '25: -196.9M Q2 '25: -229.9M Q3 '25: -252M Q4 '25: -279.1M Q1 '26: -306.4M Q2 '26: -337.5M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '14: -263K Q4 '14: -1.3M Q1 '15: -5.6M Q2 '15: -5.9M Q3 '15: -17M Q4 '15: -18.7M Q1 '16: -18.1M Q2 '16: -21.1M Q3 '16: -20.5M Q4 '16: -19.8M Q1 '17: -21.4M Q2 '17: -22.8M Q3 '17: -26.8M Q4 '17: -29M Q1 '18: -30.8M Q2 '18: -29.6M Q3 '18: -34.7M Q4 '18: -35.2M Q1 '19: -35.9M Q2 '19: -39.2M Q3 '19: -32.6M Q4 '19: -6M Q1 '20: -10.6M Q2 '20: -12.8M Q3 '20: -17.6M Q4 '20: -50.8M Q1 '21: -58.2M Q2 '21: -61M Q3 '21: -64.3M Q4 '21: -71.6M Q1 '22: -69.1M Q2 '22: -72.5M Q3 '22: -88.1M Q4 '22: -103.9M Q1 '23: -121.9M Q2 '23: -139.8M Q3 '23: -158.3M Q4 '23: -156.7M Q1 '24: -166.5M Q2 '24: -163.8M Q3 '24: -164.8M Q4 '24: -184.5M Q1 '25: -199.8M Q2 '25: -231.5M Q3 '25: -253.3M Q4 '25: -279.9M Q1 '26: -307.3M Q2 '26: -338.5M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q3 '13: 2.1M Q2 '14: 1.3M Q3 '14: 2.1M Q2 '15: 15.1M Q3 '15: 14.3M Q1 '16: 14.4M Q2 '16: 14.4M Q3 '16: 15.3M Q1 '17: 18M Q2 '17: 18M Q3 '17: 18M Q1 '18: 17.8M Q2 '18: 14.3M Q3 '18: 20.3M Q1 '19: 25.8M Q2 '19: 25.8M Q2 '20: 35M Q2 '21: 42.1M Q3 '21: 42.3M Q1 '22: 54.9M Q2 '22: 56.2M Q3 '22: 65.5M Q1 '23: 65.7M Q2 '23: 65.9M Q3 '23: 66M Q1 '24: 77.6M Q2 '24: 77.7M Q3 '24: 77.9M Q1 '25: 78.7M Q2 '25: 79M Q3 '25: 79.2M Q1 '26: 87.3M Q2 '26: 99.6M Q3 '14 Q3 '16 Q2 '18 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q2 '15: 1.11 Q3 '15: -0.85 Q4 '15: -1.25 Q1 '16: -0.84 Q2 '16: -1.19 Q3 '16: -1.43 Q4 '16: -1.48 Q1 '17: -1.68 Q2 '17: -1.67 Q3 '17: -1.59 Q4 '17: -1.72 Q1 '18: -1.50 Q2 '18: -1.54 Q3 '18: -1.74 Q4 '18: -1.58 Q1 '19: -1.79 Q2 '19: -1.71 Q3 '19: -1.41 Q4 '19: -1.53 Q1 '20: -1.33 Q2 '20: -0.96 Q3 '20: -0.88 Q4 '20: -0.81 Q1 '21: -1.01 Q2 '21: -1.52 Q3 '21: -1.63 Q4 '21: -1.77 Q1 '22: -1.70 Q2 '22: -1.74 Q3 '22: -1.95 Q4 '22: -2.04 Q1 '23: -2.32 Q2 '23: -2.49 Q3 '23: -2.65 Q4 '23: -2.72 Q1 '24: -2.71 Q2 '24: -2.74 Q3 '24: -2.82 Q4 '24: -3.02 Q1 '25: -3.23 Q2 '25: -3.55 Q3 '25: -3.89 Q4 '25: -4.36 Q1 '26: -4.70 Q2 '26: -4.74 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.